Skip to main content
ABION Inc. logo

ABION Inc. — Investor Relations & Filings

Ticker · 203400 ISIN · KR7203400007 KO Professional, scientific and technical activities
Open in API
Filings indexed 408 across all filing types
Latest filing 2025-07-11 AGM Information
Country KR South Korea
Listing KO 203400

About ABION Inc.

https://abionbio.com/en/

ABION Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines, focusing on first-in-class and best-in-class therapeutics for oncology and viral diseases. The company's lead oncology asset is ABN401, a selective c-Met tyrosine kinase inhibitor (TKI) designed to treat non-small cell lung cancer (NSCLC) with MET mutations, which has shown a favorable safety profile. Another key pipeline candidate is ABN501, a novel monoclonal antibody targeting Claudin-3 for various cancers. Beyond oncology, ABION is developing ABN101, a second-generation Interferon-β formulated as a broad-spectrum anti-viral inhaler for respiratory infections. The company aims to commercialize its assets in global markets through internationally recognized clinical processes.

Recent filings

Filing Released Lang Actions
주주총회소집결의 (임시주주총회)
AGM Information Classification · 98% confidence The document is a formal notice of an Extraordinary General Meeting (EGM) for the company 'Abion'. It details the date, time, location, and agenda items (specifically the appointment of an internal director). This type of document is a standard proxy solicitation or meeting notice provided to shareholders to inform them of upcoming voting procedures and meeting logistics. Given the specific categories provided, 'PSI' (Proxy Solicitation & Information Statement) is the most accurate classification for a notice of a shareholder meeting and its agenda.
2025-07-11 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for an Extraordinary General Meeting (EGM). It does not contain the full proxy materials or the meeting presentation itself, but rather serves as a formal notice of the record date for shareholder rights. Given the nature of the filing as a regulatory notification regarding shareholder meeting logistics, it falls under the general regulatory filing category.
2025-07-11 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership (specifically a decrease in holdings) by a major shareholder and their special relations. This type of filing is categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant changes in ownership levels.
2025-07-10 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (장내매수 - open market purchases) of an executive (Kim Yun-bum) of the company 'Abion'. This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2025-07-09 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, including major shareholding notifications and changes in special relationships. This falls under the 'Major Shareholding Notification' category.
2025-07-04 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing titled 'Correction Report' (정정신고) regarding a 'Stock Collateral Agreement Involving Change in Largest Shareholder' (최대주주 변경을 수반하는 주식 담보제공 계약 체결). It details specific changes to collateral amounts, share counts, and debt obligations. Since this is a formal regulatory disclosure regarding capital structure and collateralization of shares, it falls under the category of general regulatory filings that do not fit into more specific categories like M&A or Earnings Releases.
2025-07-04 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.